An appraisal of emerging therapeutic targets for multiple sclerosis derived from current preclinical models

References

• McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765–779. doi: 10.1001/jama.2020.26858
   PubMed Web of Science ®Google Scholar
• The Multiple Sclerosis International Federation (MSIF) TMSIF. Atlas of MS, 3rd Edition. Part 1: Mapping multiple sclerosis around the world. Key epidemiology findings. The Multiple Sclerosis International Federation (MSIF), September 2020. 3rd ed. 2020. p. 24.
   Google Scholar
• Cross AH, Naismith RT. MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No. Mult Scler. 2021 Jun;27(7):1004–1005. doi: 10.1177/13524585211001564
   PubMed Web of Science ®Google Scholar
• Scalfari A. MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes. Mult Scler. 2021 Jun;27(7):1002–1004. doi: 10.1177/13524585211001789
   PubMed Web of Science ®Google Scholar
• Greer JM, Pender MP. The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005 May;76(5):656–662. doi: 10.1136/jnnp.2004.042168
   PubMed Web of Science ®Google Scholar
• Rice CM, Cottrell D, Wilkins A, et al. Primary progressive multiple sclerosis: progress and challenges. J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1100–1106.
   PubMed Web of Science ®Google Scholar
• International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. Sep 27 2019;365(6460):eaav7188.
   PubMed Web of Science ®Google Scholar
• Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022 Jan 21;375(6578):296–301.
   PubMed Web of Science ®Google Scholar
• Breuer J, Loser K, Mykicki N, et al. Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D? J Neuroimmunol. 2019 [2019 Apr 15];329:1–8.
   PubMed Web of Science ®Google Scholar
• Lanz TV, Brewer RC, Ho PP, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022 Mar;603(7900):321–327.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhu F, Arnold D, et al. The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Ann Clin Transl Neurol. 2021 Dec;8(12):2252–2269.
   PubMed Web of Science ®Google Scholar
• Vandebergh M, Degryse N, Dubois B, et al. Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies. J Neurol. 2022 [2022 Aug 1];269(8):4565–4574. doi: 10.1007/s00415-022-11072-4
   PubMed Web of Science ®Google Scholar
• Wang X, Liang Z, Wang S, et al. Role of gut microbiota in multiple sclerosis and potential therapeutic implications. Curr Neuropharmacol. 2022;20(7):1413–1426. doi: 10.2174/1570159X19666210629145351
   PubMed Web of Science ®Google Scholar
• Cloake NC, Yan J, Aminian A, et al. PLP1 Mutations in patients with multiple sclerosis: identification of a new mutation and potential pathogenicity of the mutations. J Clin Med. 2018 Oct 11;7(10):342.
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Trapp BD. Axonal degeneration and progressive neurologic disability in multiple sclerosis.Neurotox Res. 2003 [2003 Jan 1];5(1):157–164. doi: 10.1007/BF03033380.
   PubMed Web of Science ®Google Scholar
• Lassmann H, Bradl M. Multiple sclerosis: experimental models and reality. Acta Neuropathol. 2017 Feb;133(2):223–244. doi: 10.1007/s00401-016-1631-4
   PubMed Web of Science ®Google Scholar
• McCombe PA, Greer JM. Effects of biological sex and pregnancy in experimental autoimmune encephalomyelitis: It’s complicated. Front Immunol. 2022;13:1059833. doi: 10.3389/fimmu.2022.1059833
   PubMed Web of Science ®Google Scholar
• Greer JM, Csurhes PA, Muller DM, et al. Correlation of blood T cell and antibody reactivity to myelin proteins with HLA type and lesion localization in multiple sclerosis. J Immunol. 2008 May 1;180(9):6402–6410.
   PubMed Web of Science ®Google Scholar
• Bühler M, Runft S, Li D, et al. IFN-β deficiency results in fatal or demyelinating disease in C57BL/6 mice infected with Theiler’s Murine encephalomyelitis viruses. Front Immunol. 2022;13:786940. doi: 10.3389/fimmu.2022.786940
   PubMed Web of Science ®Google Scholar
• Zhan J, Mann T, Joost S, et al. The cuprizone model: dos and do nots. Cells. 2020 Mar 31;9(4):843.
   PubMed Web of Science ®Google Scholar
• Buschmann JP, Berger K, Awad H, et al. Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination. J Mol Neurosci. 2012 Sep;48(1):66–76.
   PubMed Web of Science ®Google Scholar
• Zirngibl M, Assinck P, Sizov A, et al. Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination. Mol Neurodegener. 2022 May 7;17(1):34.
   PubMed Web of Science ®Google Scholar
• Gharagozloo M, Mace JW, Calabresi PA. Animal models to investigate the effects of inflammation on remyelination in multiple sclerosis. Front Mol Neurosci. 2022;15:995477. doi: 10.3389/fnmol.2022.995477
   PubMed Web of Science ®Google Scholar
• Hooijmans CR, Hlavica M, Schuler FAF, et al. Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis. Sci Rep. 2019 Jan 29;9(1):822.
   PubMedGoogle Scholar
• Martinez B, Peplow PV. Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014–2019. Neural Regen Res. 2020;15(7):1220. doi: 10.4103/1673-5374.272572
   PubMed Web of Science ®Google Scholar
• Melchor GS, Khan T, Reger JF, et al. Remyelination pharmacotherapy investigations highlight diverse mechanisms underlying multiple sclerosis progression. ACS Pharmacol Transl Sci. 2019 [2019 Dec 13];2(6):372–386. doi: 10.1021/acsptsci.9b00068
   PubMedGoogle Scholar
• Sutiwisesak R, Burns TC, Rodriguez M, et al. Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials. Expert Opin Investig Drugs. 2021 Aug;30(8):857–876.
   PubMed Web of Science ®Google Scholar
• Bhargava P, Kim S, Reyes AA, et al. Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition. Brain. 2021 Jun 22;144(5):1396–1408.
   PubMedGoogle Scholar
• Lang Y, Chu F, Liu L, et al. Potential role of BAY11-7082, a NF-κB blocker inhibiting experimental autoimmune encephalomyelitis in C57BL/6J mice via declining NLRP3 inflammasomes. Clin Exp Immunol. 2021 Nov 27;207(3):378–386.
   Web of Science ®Google Scholar
• Sánchez-Fernández A, Skouras DB, Dinarello CA, et al. OLT1177 (Dapansutrile), a selective NLRP3 inflammasome inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis. Front Immunol. 2019;10:2578. doi: 10.3389/fimmu.2019.02578
   PubMed Web of Science ®Google Scholar
• Lin H, Yang M, Li C, et al. An RRx-001 analogue with potent anti-NLRP3 inflammasome activity but without high-energy nitro functional groups. Front Pharmacol. 2022;13:822833. doi: 10.3389/fphar.2022.822833
   PubMed Web of Science ®Google Scholar
• Pan RY, Kong XX, Cheng Y, et al. 1,2,4-Trimethoxybenzeneselectively inhibits NLRP3 inflammasome activation and attenuates experimental autoimmune encephalomyelitis. Acta Pharmacol Sin. 2021 Nov;42(11):1769–1779.
   PubMed Web of Science ®Google Scholar
• Ren GM, Li J, Zhang XC, et al. Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases. Sci Immunol. 2021 Apr 30;6(58). doi: 10.1126/sciimmunol.abe2933
   Web of Science ®Google Scholar
• Cao R, Li Z, Wu C, et al. Identification of a small molecule with strong anti-inflammatory activity in experimental autoimmune encephalomyelitis and sepsis through blocking gasdermin D activation. J Immunol. 2022 Aug 15;209(4):820–828.
   PubMed Web of Science ®Google Scholar
• Alhazzani K, Ahmad SF, Al-Harbi NO, et al. Pharmacological inhibition of STAT3 by stattic ameliorates clinical symptoms and reduces autoinflammation in myeloid, lymphoid, and neuronal tissue compartments in relapsing–remitting model of experimental autoimmune encephalomyelitis in SJL/J mice. Pharmaceutics. 2021 Jun 22;13(7):925.
   PubMed Web of Science ®Google Scholar
• Hosseini A, Gharibi T, Mohammadzadeh A, et al. Ruxolitinib attenuates experimental autoimmune encephalomyelitis (EAE) development as animal models of multiple sclerosis (MS). Life Sci. 2021 Jul 1;276:119395.
   PubMed Web of Science ®Google Scholar
• Dang C, Lu Y, Chen X, et al. Baricitinib ameliorates experimental autoimmune encephalomyelitis by modulating the janus kinase/signal transducer and activator of transcription signaling pathway. Front Immunol. 2021;12:650708. doi: 10.3389/fimmu.2021.650708
   PubMed Web of Science ®Google Scholar
• Zhu H, Li G, Yin J, et al. Anlotinib attenuates experimental autoimmune encephalomyelitis mice model of multiple sclerosis via modulating the differentiation of Th17 and Treg cells. Immunopharmacol Immunotoxicol. 2022 Aug;44(4):594–602.
   PubMed Web of Science ®Google Scholar
• Park J, Choi SW, Cha BG, et al. Alternative activation of macrophages through interleukin-13-loaded extra-large-pore mesoporous silica nanoparticles suppresses experimental autoimmune encephalomyelitis. ACS Biomater Sci Eng. 2021 Sep 13;7(9):4446–4453.
   PubMed Web of Science ®Google Scholar
• Sánchez-Fernández A, Zandee S, Mastrogiovanni M, et al. Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis. J Neuroinflammation. 2022 Feb 2;19(1):27.
   PubMed Web of Science ®Google Scholar
• Bae D, Lee JY, Ha N, et al. CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis. Sci Rep. 2021 Jul 14;11(1):14466.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Pascau L, Vilalta A, Cerrada M, et al. The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy. Sci Transl Med. 2021 Jun 2;13(596). doi: 10.1126/scitranslmed.abc0555
   PubMed Web of Science ®Google Scholar
• Zahoor I, Suhail H, Datta I, et al. Blood-based untargeted metabolomics in relapsing-remitting multiple sclerosis revealed the testable therapeutic target. Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2123265119.
   PubMed Web of Science ®Google Scholar
• Che J, Li D, Hong W, et al. Discovery of new macrophage M2 polarization modulators as multiple sclerosis treatment agents that enable the inflammation microenvironment remodeling. Eur J Med Chem. 2022 Sep 2;243:114732.
   PubMed Web of Science ®Google Scholar
• Cai F, Liu S, Lei Y, et al. Epigallocatechin-3 gallate regulates macrophage subtypes and immunometabolism to ameliorate experimental autoimmune encephalomyelitis. Cell Immunol. 2021 Oct;368:104421.
   PubMed Web of Science ®Google Scholar
• Karsten S, Fiskesund R, Zhang XM, et al. MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells. Cell Death Differ. 2022 Jan;29(1):246–261.
   PubMed Web of Science ®Google Scholar
• Kim K, Pröbstel AK, Baumann R, et al. Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis. Brain. 2021 Mar 3;144(2):450–461.
   PubMed Web of Science ®Google Scholar
• Li H, Liu S, Han J, et al. Role of toll-like receptors in neuroimmune diseases: therapeutic targets and problems. Front Immunol. 2021;12:777606. doi: 10.3389/fimmu.2021.777606
   PubMed Web of Science ®Google Scholar
• Dresselhaus EC, Meffert MK. Cellular specificity of NF-kappaB function in the nervous system. Front Immunol. 2019;10:1043. doi: 10.3389/fimmu.2019.01043
   PubMed Web of Science ®Google Scholar
• Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015 Jul;21(7):677–687. doi: 10.1038/nm.3893
   PubMed Web of Science ®Google Scholar
• Chen Y, He H, Lin B, et al. Rrx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. Cell Mol Immunol. 2021 Jun;18(6):1425–1436.
   PubMed Web of Science ®Google Scholar
• Biname F, Pham-Van LD, Spenle C, et al. Disruption of Sema3A/Plexin-A1 inhibitory signalling in oligodendrocytes as a therapeutic strategy to promote remyelination. EMBO Mol Med. 2019 Nov 7;11(11):e10378.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Kumanogoh A, Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat Immunol. 2008 Jan;9(1):17–23. doi: 10.1038/ni1553
   PubMed Web of Science ®Google Scholar
• Liu Y, Gibson SA, Benveniste EN, et al. Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in neuroinflammatory diseases. Crit Rev Immunol. 2015;35(6):505–527. doi: 10.1615/CritRevImmunol.2016015517
   PubMed Web of Science ®Google Scholar
• Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021 Nov 26;6(1):402.
   PubMed Web of Science ®Google Scholar
• Liu D, Zhao Z, She Y, et al. TRIM14 inhibits OPTN-mediated autophagic degradation of KDM4D to epigenetically regulate inflammation. Proc Natl Acad Sci U S A. 2022 Feb 15;119(7). doi: 10.1073/pnas.2113454119
   Web of Science ®Google Scholar
• Mills EL, Kelly B, O’Neill LAJ. Mitochondria are the powerhouses of immunity. Nat Immunol. 2017 Apr 18;18(5):488–498.
   PubMed Web of Science ®Google Scholar
• Buck MD, O’Sullivan D, Pearce EL. T cell metabolism drives immunity. J Exp Med. 2015 Aug 24;212(9):1345–1360.
   PubMed Web of Science ®Google Scholar
• Linke M, Fritsch SD, Sukhbaatar N, et al. mTORC1 and mTORC2 as regulators of cell metabolism in immunity. FEBS Lett. 2017 Oct;591(19):3089–3103.
   PubMed Web of Science ®Google Scholar
• Hernandez-Quiles M, Broekema MF, Kalkhoven E. Ppargamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action. Front Endocrinol. 2021;12:624112. doi: 10.3389/fendo.2021.624112
   PubMed Web of Science ®Google Scholar
• Varga T, Czimmerer Z, Nagy L. Ppars are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta. 2011 Aug;1812(8):1007–1022. doi: 10.1016/j.bbadis.2011.02.014
   PubMed Web of Science ®Google Scholar
• Everts HB, Berdanier CD. Regulation of mitochondrial gene expression by retinoids. IUBMB Life. 2002 Aug;54(2):45–49. doi: 10.1080/15216540214316
   PubMed Web of Science ®Google Scholar
• Grzywa TM, Sosnowska A, Matryba P, et al. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020;11:938. doi: 10.3389/fimmu.2020.00938
   PubMed Web of Science ®Google Scholar
• Morita M, Gravel SP, Hulea L, et al. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle. 2015;14(4):473–480. doi: 10.4161/15384101.2014.991572
   PubMed Web of Science ®Google Scholar
• Kim TW, Kim Y, Jung W, et al. Bilirubin nanomedicine ameliorates the progression of experimental autoimmune encephalomyelitis by modulating dendritic cells. J Control Release. 2021 Mar 10;331:74–84. doi: 10.1016/j.jconrel.2021.01.019
   PubMed Web of Science ®Google Scholar
• Zha Z, Liu S, Liu Y, et al. Potential utility of natural products against oxidative stress in animal models of multiple sclerosis. Antioxid (Basel). 2022 Jul 29;11(8):1495.
   PubMedGoogle Scholar
• Rutsch A, Kantsjö JB, Ronchi F. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Front Immunol. 2020;11:604179. doi: 10.3389/fimmu.2020.604179
   PubMed Web of Science ®Google Scholar
• Baecher-Allan CM, Costantino CM, Cvetanovich GL, et al. CD2 costimulation reveals defective activity by human CD4+CD25(hi) regulatory cells in patients with multiple sclerosis. J Immunol. 2011 Mar 15;186(6):3317–3326.
   PubMed Web of Science ®Google Scholar
• Axisa PP, Yoshida TM, Lucca LE, et al. A multiple sclerosis-protective coding variant reveals an essential role for HDAC7 in regulatory T cells. Sci Transl Med. 2022 Dec 14;14(675):eabl3651.
   PubMed Web of Science ®Google Scholar
• Yshii L, Pasciuto E, Bielefeld P, et al. Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation. Nat Immunol. 2022 Jun;23(6):878–891. doi: 10.1038/s41590-022-01208-z
   PubMed Web of Science ®Google Scholar
• Kenison JE, Jhaveri A, Li Z, et al. Tolerogenic nanoparticles suppress central nervous system inflammation. Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32017–32028.
   PubMed Web of Science ®Google Scholar
• Krienke C, Kolb L, Diken E, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371(6525):145–153. doi: 10.1126/science.aay3638
   PubMed Web of Science ®Google Scholar
• Zhou H, Lou F, Bai J, et al. A peptide encoded by pri-miRNA-31 represses autoimmunity by promoting T(reg) differentiation. EMBO Rep. 2022 May 4;23(5):e53475.
   PubMed Web of Science ®Google Scholar
• Feng C, Li L, Li Q, et al. Docosahexaenoic acid ameliorates autoimmune inflammation by activating GPR120 signaling pathway in dendritic cells. Int Immunopharmacol. 2021 Aug;97:107698.
   PubMed Web of Science ®Google Scholar
• Hou H, Sun Y, Miao J, et al. Ponesimod modulates the Th1/Th17/Treg cell balance and ameliorates disease in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2021 [2021 Jul 15];356:577583.
   PubMed Web of Science ®Google Scholar
• Fujiwara M, Raheja R, Garo LP, et al. MicroRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance. J Clin Invest. 2022 May 16;132(10). doi: 10.1172/JCI155693
   Web of Science ®Google Scholar
• Hwang D, Boehm A, Rostami A, et al. Oral D-mannose treatment suppresses experimental autoimmune encephalomyelitis via induction of regulatory T cells. J Neuroimmunol. 2022 Jan 15;362:577778.
   PubMed Web of Science ®Google Scholar
• Shepard ER, Wegner A, Hill EV, et al. The mechanism of action of antigen processing independent T cell epitopes designed for immunotherapy of autoimmune diseases. Front Immunol. 2021;12:654201. doi: 10.3389/fimmu.2021.654201
   PubMed Web of Science ®Google Scholar
• Korn T, Muschaweckh A. Stability and maintenance of foxp3(+) treg cells in non-lymphoid microenvironments. Front Immunol. 2019;10:2634. doi: 10.3389/fimmu.2019.02634
   PubMed Web of Science ®Google Scholar
• Pohar J, O’Connor R, Manfroi B, et al. Antigen receptor-engineered Tregs inhibit CNS autoimmunity in cell therapy using nonredundant immune mechanisms in mice. Eur J Immunol. 2022 Aug;52(8):1335–1349.
   PubMed Web of Science ®Google Scholar
• Sauer EL, Cloake NC, Greer JM. Taming the TCR: antigen-specific immunotherapeutic agents for autoimmune diseases. Int Rev Immunol. 2015;34(6):460–485. doi: 10.3109/08830185.2015.1027822
   PubMed Web of Science ®Google Scholar
• Pfeil J, Simonetti M, Lauer U, et al. Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides. Ther Adv Chronic Dis. 2021;12:20406223211037830. doi: 10.1177/20406223211037830
   Web of Science ®Google Scholar
• Wang H, Shang J, He Z, et al. Dual peptide nanoparticle platform for enhanced antigen-specific immune tolerance for the treatment of experimental autoimmune encephalomyelitis. Biomater Sci. 2022 Jul 12;10(14):3878–3891.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Agata K, Takasugi S, et al. New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect. J Control Release. 2021 Jul 10;335:389–397.
   PubMed Web of Science ®Google Scholar
• Ceylan U, Haupeltshofer S, Kämper L, et al. Clozapine regulates microglia and is effective in chronic experimental autoimmune encephalomyelitis. Front Immunol. 2021;12:656941. doi: 10.3389/fimmu.2021.656941
   PubMed Web of Science ®Google Scholar
• Duan W, Sun Y, Wu M, et al. Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis. Eur J Med Chem. 2021 Dec 15;226:113878.
   PubMed Web of Science ®Google Scholar
• Gonçalves ECD, Lieberknecht V, Horewicz VV, et al. Dopaminergic receptors as neuroimmune mediators in experimental autoimmune encephalomyelitis. Mol Neurobiol. 2021 Nov;58(11):5971–5985.
   PubMed Web of Science ®Google Scholar
• Melnikov M, Pashenkov M, Boyko A. Dopaminergic receptor targeting in multiple sclerosis: is there therapeutic potential? Int J Mol Sci. 2021 May 18;22(10):5313.
   PubMed Web of Science ®Google Scholar
• Parastouei K, Aarabi MH, Hamidi GA, et al. A CB2 receptor agonist reduces the production of inflammatory mediators and improves locomotor activity in experimental autoimmune encephalomyelitis. Rep Biochem Mol Biol. 2022 Apr;11(1):1–9.
   PubMed Web of Science ®Google Scholar
• Reynoso-Moreno I, Tietz S, Vallini E, et al. Selective endocannabinoid reuptake inhibitor WOBE437 reduces disease progression in a mouse model of multiple sclerosis. ACS Pharmacol Transl Sci. 2021 Apr 9;4(2):765–779.
   PubMedGoogle Scholar
• Tiberi M, Evron T, Saracini S, et al. Potent T cell-mediated anti-inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis. Neuropathol Appl Neurobiol. 2022 Feb;48(2):e12768.
   PubMed Web of Science ®Google Scholar
• Bhat R, Axtell R, Mitra A, et al. Inhibitory role for GABA in autoimmune inflammation. Proc Nat Acad Sci. 2010;107(6):2580–2585. doi: 10.1073/pnas.0915139107
   PubMed Web of Science ®Google Scholar
• Parodi B, Kerlero de Rosbo N. The gut-brain axis in multiple sclerosis. is its dysfunction a pathological trigger or a consequence of the disease? Front Immunol. 2021;12:718220. doi: 10.3389/fimmu.2021.718220
   PubMed Web of Science ®Google Scholar
• Rebeaud J, Peter B, Pot C. How microbiota-derived metabolites link the gut to the brain during neuroinflammation. Int J Mol Sci. 2022 Sep 4;23(17):10128.
   PubMed Web of Science ®Google Scholar
• Heng AHS, Han CW, Abbott C, et al. Chemokine-driven migration of pro-inflammatory CD4(+) T cells in CNS autoimmune disease. Front Immunol. 2022;13:817473. doi: 10.3389/fimmu.2022.817473
   PubMed Web of Science ®Google Scholar
• Al-Mazroua HA, Nadeem A, Ansari MA, et al. CCR1 antagonist ameliorates experimental autoimmune encephalomyelitis by inhibition of Th9/Th22-related markers in the brain and periphery. Mol Immunol. 2022 Apr;144:127–137.
   PubMed Web of Science ®Google Scholar
• Ahmad SF, Nadeem A, Ansari MA, et al. CC chemokine receptor 5 antagonist alleviates inflammation by regulating IFN-γ/IL-10 and STAT4/Smad3 signaling in a mouse model of autoimmune encephalomyelitis. Cell Immunol. 2022 Sep;379:104580.
   PubMed Web of Science ®Google Scholar
• Karampoor S, Zahednasab H, Amini R, et al. Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis. Int Immunopharmacol. 2020 Mar;80:106138.
   PubMed Web of Science ®Google Scholar
• Shi X, Wan Y, Wang N, et al. Selection of a picomolar antibody that targets CXCR2-mediated neutrophil activation and alleviates EAE symptoms. Nat Commun. 2021 May 5;12(1):2547.
   PubMed Web of Science ®Google Scholar
• Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res. 2008 Feb 15;102(3):283–294.
   PubMed Web of Science ®Google Scholar
• Bogie JFJ, Grajchen E, Wouters E, et al. Stearoyl-CoA desaturase-1 impairs the reparative properties of macrophages and microglia in the brain. J Exp Med. 2020 May 4;217(5). doi: 10.1084/jem.20191660
   PubMed Web of Science ®Google Scholar
• Narine M, Colognato H. Current Insights into oligodendrocyte metabolism and its power to sculpt the myelin landscape. Front Cell Neurosci. 2022;16:892968. doi: 10.3389/fncel.2022.892968
   PubMed Web of Science ®Google Scholar
• Yang H, Andersson U, Brines M. Neurons are a primary driver of inflammation via release of HMGB1. Cells. 2021 Oct 18;10(10):2791.
   PubMed Web of Science ®Google Scholar
• Steudler J, Ecott T, Ivan DC, et al. Autoimmune neuroinflammation triggers mitochondrial oxidation in oligodendrocytes. Glia. 2022 Nov;70(11):2045–2061.
   PubMed Web of Science ®Google Scholar
• Yang G, Van Kaer L. Therapeutic targeting of immune cell autophagy in multiple sclerosis: russian roulette or silver bullet? [Review]. Front Immunol. 2021 [2021 Aug 31];12:12. doi: 10.3389/fimmu.2021.724108
   Web of Science ®Google Scholar
• Yu H, Bai S, Hao Y, et al. Fatty acids role in multiple sclerosis as “metabokines”. J Neuroinflammation. 2022 Jun 17;19(1):157.
   PubMed Web of Science ®Google Scholar
• Islam SMT, Won J, Kim J, et al. Detoxification of reactive aldehydes by alda-1 treatment ameliorates experimental autoimmune encephalomyelitis in mice. Neuroscience. 2021 Mar 15;458:31–42.
   PubMed Web of Science ®Google Scholar
• Cheng A, Jia W, Kawahata I, et al. A novel fatty acid-binding protein 5 and 7 inhibitor ameliorates oligodendrocyte injury in multiple sclerosis mouse models. EBioMedicine. 2021 Oct;72:103582.
   PubMed Web of Science ®Google Scholar
• Chen Y, Kunjamma RB, Weiner M, et al. Prolonging the integrated stress response enhances CNS remyelination in an inflammatory environment. Elife. 2021 Mar 23;10. doi:10.7554/eLife.65469
   Web of Science ®Google Scholar
• Uyeda A, Quan L, Kato Y, et al. Dimethylarginine dimethylaminohydrolase 1 as a novel regulator of oligodendrocyte differentiation in the central nervous system remyelination. Glia. 2021 Nov;69(11):2591–2604.
   PubMed Web of Science ®Google Scholar
• Langley MR, Choi CI, Peclat TR, et al. Critical role of astrocyte NAD(+) glycohydrolase in myelin injury and regeneration. J Neurosci. 2021 Oct 13;41(41):8644–8667.
   PubMed Web of Science ®Google Scholar
• Rothammer N, Woo MS, Bauer S, et al. G9a dictates neuronal vulnerability to inflammatory stress via transcriptional control of ferroptosis. Sci Adv. 2022 Aug 5;8(31):eabm5500.
   PubMed Web of Science ®Google Scholar
• Michaličková D, Kübra Öztürk H, Hroudová J, et al. Edaravone attenuates disease severity of experimental auto-immune encephalomyelitis and increases gene expression of Nrf2 and HO-1. Physiol Res. 2022 Mar 25;71(1):147–157.
   PubMed Web of Science ®Google Scholar
• Li QY, Miao Q, Sui RX, et al. Ginkgolide K supports remyelination via induction of astrocytic IGF/PI3K/Nrf2 axis. Int Immunopharmacol. 2019 Oct;75:105819.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Tian J, Wu WC, et al. Targeting central nervous system extracellular vesicles enhanced triiodothyronine remyelination effect on experimental autoimmune encephalomyelitis. Bioact Mater. 2022 Mar;9:373–384.
   PubMed Web of Science ®Google Scholar
• Sy M, Brandt AU, Lee SU, et al. N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation. J Biol Chem. 2020 Dec 18;295(51):17413–17424. doi: 10.1074/jbc.RA120.015595
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang D, Sun J, et al. Huperzine—A improved animal behavior in cuprizone-induced mouse model by alleviating demyelination and neuroinflammation. IJMS. 2022 Dec 19;23(24):16182.
   Google Scholar
• Shao Q, Zhao M, Pei W, et al. Pinocembrin promotes OPC differentiation and remyelination via the mTOR signaling pathway. Neurosci Bull. 2021 Sep;37(9):1314–1324.
   PubMed Web of Science ®Google Scholar
• Serrano-Regal MP, Bayón-Cordero L, Chara Ventura JC, et al. GABAB receptor agonist baclofen promotes central nervous system remyelination. Glia. 2022;70(12):2426–2440. doi: 10.1002/glia.24262
   PubMed Web of Science ®Google Scholar
• Titus HE, Xu H, Robinson AP, et al. Repurposing the cardiac glycoside digoxin to stimulate myelin regeneration in chemically-induced and immune-mediated mouse models of multiple sclerosis. Glia. 2022 Oct;70(10):1950–1970.
   PubMed Web of Science ®Google Scholar
• Paton KF, Robichon K, Templeton N, et al. The salvinorin analogue, ethoxymethyl ether salvinorin b, promotes remyelination in preclinical models of multiple sclerosis. Front Neurol. 2021;12:782190. doi: 10.3389/fneur.2021.782190
   PubMed Web of Science ®Google Scholar
• Mausner-Fainberg K, Benhamou M, Golan M, et al. Specific blockade of bone morphogenetic protein-2/4 induces oligodendrogenesis and remyelination in demyelinating disorders. Neurotherapeutics. 2021 Jul;18(3):1798–1814.
   PubMed Web of Science ®Google Scholar
• Cignarella F, Filipello F, Bollman B, et al. TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathol. 2020 [2020 Oct 1];140(4):513–534. doi: 10.1007/s00401-020-02193-z
   PubMed Web of Science ®Google Scholar
• Jing Y, Ma R, Chu Y, et al. Matrine treatment induced an A2 astrocyte phenotype and protected the blood-brain barrier in CNS autoimmunity. J Chem Neuroanat. 2021 Nov;117:102004.
   PubMed Web of Science ®Google Scholar
• Zamora NN, Cheli VT, Santiago González DA, et al. Deletion of voltage-gated calcium channels in astrocytes during demyelination reduces brain inflammation and promotes myelin regeneration in mice. J Neurosci. 2020 Apr 22;40(17):3332–3347.
   PubMed Web of Science ®Google Scholar
• Linnerbauer M, Lößlein L, Farrenkopf D, et al. Astrocyte-derived pleiotrophin mitigates late-stage autoimmune CNS inflammation. Front Immunol. 2021;12:800128. doi: 10.3389/fimmu.2021.800128
   PubMed Web of Science ®Google Scholar
• Deerhake ME, Danzaki K, Inoue M, et al. Dectin-1 limits autoimmune neuroinflammation and promotes myeloid cell-astrocyte crosstalk via Card9-independent expression of Oncostatin M. Immunity. 2021 Mar 9;54(3):484–498.e8.
   PubMed Web of Science ®Google Scholar
• Huang L, Fung E, Bose S, et al. Elezanumab, a clinical stage human monoclonal antibody that selectively targets repulsive guidance molecule a to promote neuroregeneration and neuroprotection in neuronal injury and demyelination models. Neurobiol Dis. 2021 Nov;159:105492. doi: 10.1016/j.nbd.2021.105492
   PubMed Web of Science ®Google Scholar
• Bernardo A, De Simone R, De Nuccio C, et al. The nuclear receptor peroxisome proliferator-activated receptor-γ promotes oligodendrocyte differentiation through mechanisms involving mitochondria and oscillatory Ca2+ waves. Biol Chem. 2013 Dec;394(12):1607–1614.
   PubMed Web of Science ®Google Scholar
• Jeffries MA, McLane LE, Khandker L, et al. mTOR Signaling regulates metabolic function in oligodendrocyte precursor cells and promotes efficient brain remyelination in the cuprizone model. J Neurosci. 2021 Oct 6;41(40):8321–8337.
   PubMed Web of Science ®Google Scholar
• Ornelas IM, Khandker L, Wahl SE, et al. The mechanistic target of rapamycin pathway downregulates bone morphogenetic protein signaling to promote oligodendrocyte differentiation. Glia. 2020 Jun;68(6):1274–1290.
   PubMed Web of Science ®Google Scholar
• Cherchi F, Bulli I, Venturini M, et al. Ion Channels as new attractive targets to improve re-myelination processes in the brain. Int J Mol Sci. 2021 Jul 6;22(14):7277.
   PubMed Web of Science ®Google Scholar
• Escartin C, Galea E, Lakatos A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021 Mar;24(3):312–325.
   PubMed Web of Science ®Google Scholar
• Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017 Jan 26;541(7638):481–487.
   PubMed Web of Science ®Google Scholar
• Gorter RP, Baron W. Recent insights into astrocytes as therapeutic targets for demyelinating diseases. Curr Opin Pharmacol. 2022 Aug;65:102261. doi: 10.1016/j.coph.2022.102261
   PubMed Web of Science ®Google Scholar
• Vergara RC, Jaramillo-Riveri S, Luarte A, et al. The energy homeostasis principle: neuronal energy regulation drives local network dynamics generating behavior. Front Comput Neurosci. 2019;13:49. doi: 10.3389/fncom.2019.00049
   PubMed Web of Science ®Google Scholar
• Rose J, Brian C, Pappa A, et al. Mitochondrial metabolism in astrocytes regulates brain bioenergetics, neurotransmission and redox balance. Front Neurosci. 2020;14:536682. doi: 10.3389/fnins.2020.536682
   PubMed Web of Science ®Google Scholar
• Poplawski GHD, Kawaguchi R, Van Niekerk E, et al. Injured adult neurons regress to an embryonic transcriptional growth state. Nature. 2020 2020 Mar 1;581(7806):77–82. doi: 10.1038/s41586-020-2200-5
   PubMed Web of Science ®Google Scholar
• Renthal W, Tochitsky I, Yang L, et al. Transcriptional reprogramming of distinct peripheral sensory neuron subtypes after axonal injury. Neuron. 2020 Oct 14;108(1):128–144 e9.
   PubMed Web of Science ®Google Scholar
• Ludwin SK, Rao VT, Moore CS, et al. Astrocytes in multiple sclerosis. Mult Scler J. 2016;22(9):1114–1124. doi: 10.1177/1352458516643396
   PubMed Web of Science ®Google Scholar
• Carulli D, de Winter F, Verhaagen J. Semaphorins in adult nervous system plasticity and disease. Front Synaptic Neurosci. 2021;13:672891. doi: 10.3389/fnsyn.2021.672891
   PubMed Web of Science ®Google Scholar
• Geoffroy CC, Zheng B. Chapter 9 - myelin-associated inhibitors in axonal growth after central nervous system injury. In: So K-F, and Xu X-M, editors. Neural Regeneration. Oxford: Academic Press; 2015. p. 153–170. doi: 10.1016/B978-0-12-801732-6.00009-4
   Google Scholar
• Uyeda A, Muramatsu R. Molecular mechanisms of central nervous system axonal regeneration and remyelination: a review. Int J Mol Sci. 2020 Oct 30;21(21):8116.
   PubMed Web of Science ®Google Scholar
• Cooke P, Janowitz H, Dougherty SE. Neuronal redevelopment and the regeneration of neuromodulatory axons in the adult mammalian central nervous system. Front Cell Neurosci. 2022;16:872501. doi: 10.3389/fncel.2022.872501
   PubMed Web of Science ®Google Scholar
• Kwiecien JM. Barriers to axonal regeneration after spinal cord injury: a current perspective. Neural Regen Res. 2022 Jan;17(1):85–86. doi: 10.4103/1673-5374.314299
   PubMed Web of Science ®Google Scholar
• Hawthorne AL, Hu H, Kundu B, et al. The unusual response of serotonergic neurons after CNS Injury: lack of axonal dieback and enhanced sprouting within the inhibitory environment of the glial scar. J Neurosci. 2011 Apr 13;31(15):5605–5616.
   PubMed Web of Science ®Google Scholar
• Dougherty SE, Kajstura TJ, Jin Y, et al. Catecholaminergic axons in the neocortex of adult mice regrow following brain injury. Exp Neurol. 2020 Jan;323:113089.
   PubMed Web of Science ®Google Scholar
• Ledeen R, Wu G. Gangliosides of the Nervous System. In: Sonnino S Prinetti A, editors Gangliosides: methods and Protocols. (NY) NY: Springer New York; 2018. p. 19–55.
   Google Scholar
• Mita S, de Monasterio-Schrader P, Funfschilling U, et al. Transcallosal projections require glycoprotein m6-dependent neurite growth and guidance. Cereb Cortex. 2015 Nov;25(11):4111–4125.
   PubMed Web of Science ®Google Scholar
• Leon A, Aparicio GI, Scorticati C. Neuronal glycoprotein m6a: an emerging molecule in chemical synapse formation and dysfunction. Front Synaptic Neurosci. 2021;13:661681. doi: 10.3389/fnsyn.2021.661681
   PubMed Web of Science ®Google Scholar
• Greer JM, Trifilieff E, Pender MP. Correlation between anti-myelin Proteolipid Protein (PLP) antibodies and disease severity in multiple sclerosis patients with plp response-permissive HLA types. Front Immunol. 2020;11:1891. doi: 10.3389/fimmu.2020.01891
   PubMed Web of Science ®Google Scholar
• Sobel RA, Eaton MJ, Jaju PD, et al. Anti-myelin proteolipid protein peptide monoclonal antibodies recognize cell surface proteins on developing neurons and inhibit their differentiation. J Neuropathol Exp Neurol. 2019 Sep 1;78(9):819–843. doi: 10.1093/jnen/nlz058
   PubMed Web of Science ®Google Scholar